|
DE69629108T2
(de)
*
|
1995-02-24 |
2004-04-22 |
Weg, Stuart L. |
Anwendung von ketamin zur entgiftung
|
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
AU2003268026A1
(en)
|
2002-07-30 |
2004-02-16 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
AU2003291037A1
(en)
*
|
2002-11-18 |
2004-06-15 |
Yaupon Therapeutics, Inc. |
Analgesic uses of norketamine and ketamine/norketamine prodrugs
|
|
US10172810B2
(en)
|
2003-02-24 |
2019-01-08 |
Pharmaceutical Productions, Inc. |
Transmucosal ketamine delivery composition
|
|
ATE433993T1
(de)
|
2003-02-26 |
2009-07-15 |
Univ Johns Hopkins |
Modulatorische verbindungen und verfahren für glutamattransport
|
|
AU2004229551A1
(en)
|
2003-04-14 |
2004-10-28 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
|
MXPA06011891A
(es)
|
2004-04-20 |
2007-04-24 |
Pfizer |
Metodo para tratar el dolor neuropatico.
|
|
US20060240043A1
(en)
|
2004-10-08 |
2006-10-26 |
Meyerson Laurence R |
Methods and compositions for treating migraine pain
|
|
US20080096872A1
(en)
|
2004-12-22 |
2008-04-24 |
Friedman Robert S |
Composition for Treatment of Pain Specification
|
|
EP1855686A1
(en)
|
2005-03-01 |
2007-11-21 |
Pfizer Limited |
Use of pde7 inhibitors for the treatment of neuropathic pain
|
|
JP2008531158A
(ja)
|
2005-03-04 |
2008-08-14 |
メンティス キュラ イーエイチエフ． |
神経学的状態を評価する方法および系
|
|
JP5666087B2
(ja)
|
2005-04-06 |
2015-02-12 |
アダマス・ファーマシューティカルズ・インコーポレーテッド |
Ｃｎｓ関連疾患の治療のための方法及び組成物
|
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
|
KR101529318B1
(ko)
|
2005-12-19 |
2015-06-16 |
파마인 코포레이션 |
치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
|
|
WO2007111880A2
(en)
*
|
2006-03-22 |
2007-10-04 |
Mount Sinai School Of Medicine |
Intranasal administration of ketamine to treat depression
|
|
US20090306137A1
(en)
|
2006-05-22 |
2009-12-10 |
Wolfgang Curt D |
Treatment for depressive disorders
|
|
EP1902733A1
(en)
|
2006-09-19 |
2008-03-26 |
Laboratorios Del Dr. Esteve, S.A. |
Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
|
|
AU2008279572A1
(en)
|
2007-02-01 |
2009-01-29 |
David Chau |
Combinations of dopamine D2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
WO2008140859A1
(en)
|
2007-03-15 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
|
|
WO2008141057A1
(en)
|
2007-05-08 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
|
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
|
US20100316678A1
(en)
|
2007-06-28 |
2010-12-16 |
Cnsbio Pty Ltd. |
Combination methods and compositions for treatment of neuropathic pain
|
|
US7828771B2
(en)
|
2007-07-26 |
2010-11-09 |
Entra Pharmaceuticals, Inc. |
Systems and methods for delivering drugs
|
|
WO2009021058A2
(en)
|
2007-08-06 |
2009-02-12 |
Trinity Labortories, Inc. |
Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
|
|
JP2010540454A
(ja)
|
2007-09-21 |
2010-12-24 |
アカディア ファーマシューティカルズ，インコーポレーテッド |
ピマバンセリンと他の薬剤との併用投与
|
|
US20100297181A1
(en)
|
2007-12-26 |
2010-11-25 |
Eisai R&D Management Co., Ltd. |
AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US20140037718A1
(en)
|
2009-03-06 |
2014-02-06 |
George W. Lutz |
Transdermal pain gel
|
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
DK3254676T3
(en)
|
2009-10-30 |
2019-03-11 |
Ix Biopharma Ltd |
QUICK-SOLVING SOLID DOSAGE FORM
|
|
CN107468211A
(zh)
|
2010-01-18 |
2017-12-15 |
艾欧敏达有限公司 |
用于分析神经生理学数据的方法和系统以及评估系统
|
|
WO2013003669A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of South Florida |
Compositions, methods of use, and methods of treatment
|
|
JP2015501652A
(ja)
|
2011-12-14 |
2015-01-19 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
Ｇａｂｒ−ａ２診断
|
|
PE20141906A1
(es)
|
2012-03-12 |
2014-12-05 |
Janssen Pharmaceutica Nv |
Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
|
|
EP2830604A4
(en)
|
2012-03-30 |
2015-08-19 |
Gen Hospital Corp |
COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS
|
|
US20120323214A1
(en)
|
2012-05-16 |
2012-12-20 |
Totada R Shantha |
Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
|
|
WO2014020155A1
(en)
|
2012-08-02 |
2014-02-06 |
Clinpharm Reform Gmbh |
Oral transmucosal adminstration forms of s-ketamine
|
|
JP6722453B2
(ja)
|
2012-08-23 |
2020-07-15 |
スチュアート エル ウェグ |
抗不安薬組成物、製剤および使用方法
|
|
US8974365B2
(en)
|
2012-11-25 |
2015-03-10 |
Steven Richard Devore Best |
Treatment of thalamocortical dysrhythmia
|
|
WO2014100501A1
(en)
|
2012-12-20 |
2014-06-26 |
Sanford-Burnham Medical Research Institute |
Small molecule agonists of neurotensin receptor 1
|
|
CN116251084A
(zh)
|
2013-03-15 |
2023-06-13 |
詹森药业有限公司 |
S-盐酸氯胺酮的药物组合物
|
|
PE20200404A1
(es)
|
2013-03-15 |
2020-02-26 |
Janssen Pharmaceutica Nv |
Composicion farmaceutica de clorhidrato de s-ketamina
|
|
JP6473738B2
(ja)
|
2013-04-01 |
2019-02-20 |
パルマトリックス，インコーポレイテッド |
チオトロピウム乾燥粉末
|
|
US9913803B2
(en)
|
2013-08-26 |
2018-03-13 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
SI3043785T1
(sl)
|
2013-09-13 |
2022-02-28 |
National University Corporation Chiba University |
Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
|
|
CA2936809A1
(en)
|
2014-01-14 |
2015-07-23 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
DK3272338T3
(da)
|
2014-04-17 |
2020-11-02 |
Develco Pharma Schweiz Ag |
Oral doseringsform for ketamin
|
|
KR20170013890A
(ko)
|
2014-05-06 |
2017-02-07 |
노쓰웨스턴유니버시티 |
Nmdar 조절 화합물의 조합물
|
|
US11207316B2
(en)
|
2014-05-30 |
2021-12-28 |
West Virginia University |
Ketamine or dextromethorphan formulations and methods of use
|
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
|
CN106714789A
(zh)
|
2014-08-13 |
2017-05-24 |
詹森药业有限公司 |
用于治疗抑郁症的方法
|
|
CN107208133A
(zh)
|
2014-09-15 |
2017-09-26 |
詹森药业有限公司 |
用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
|
|
KR20170095807A
(ko)
|
2014-10-07 |
2017-08-23 |
램 테라퓨틱스, 인코포레이티드 |
폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
|
|
AU2015343083B2
(en)
|
2014-11-04 |
2020-07-23 |
Acadia Pharmaceuticals Inc. |
Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
|
|
JP6696994B2
(ja)
|
2014-12-08 |
2020-05-20 |
クレシオ・バイオサイエンシズ・リミテッド |
即放性乱用抑止性顆粒剤形
|
|
WO2016109427A1
(en)
|
2014-12-31 |
2016-07-07 |
Icahn School Of Medicine At Mount Sinai |
Method of maintaining the anti-depressant effect of ketamine with lithium
|
|
WO2016112467A1
(en)
|
2015-01-15 |
2016-07-21 |
Centre For Addiction And Mental Health |
Peripheral measure of central brain inflammation, markers therefor and uses thereof
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
WO2016201299A1
(en)
|
2015-06-12 |
2016-12-15 |
Indiana University Research & Technology Corporation |
Predicting suicidality using a combined genomic and clinical risk assessment
|
|
US11191734B2
(en)
|
2015-06-27 |
2021-12-07 |
Shenox Pharmaceuticals, Llc |
Ketamine transdermal delivery system
|
|
CN106562952B
(zh)
*
|
2015-10-09 |
2020-06-09 |
江阴安博生物医药有限公司 |
氯胺酮在治疗重性抑郁障碍中的应用
|
|
JP2018530593A
(ja)
|
2015-10-16 |
2018-10-18 |
ノースウェスタン ユニバーシティ |
統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにｎｍｄａ調節剤の医薬品の組み合わせ
|
|
US10881637B2
(en)
|
2015-11-17 |
2021-01-05 |
Atlee Solomon |
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
|
|
EP3377050A4
(en)
|
2015-11-17 |
2019-11-20 |
The Trustees of Columbia University in the City of New York |
PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
|
|
US20180296478A1
(en)
|
2016-02-12 |
2018-10-18 |
Synergistic Therapeutics, Llc |
Sublingual antidepressant and antianxiety tablet
|
|
US20180042936A1
(en)
|
2016-03-18 |
2018-02-15 |
Genomind, Inc. |
Maintenance therapy using tianeptine
|
|
CA3019012A1
(en)
|
2016-03-25 |
2017-09-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
|
|
US11213495B2
(en)
|
2016-05-25 |
2022-01-04 |
National Health Research Institutes |
Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
|
|
JP7556688B2
(ja)
|
2016-07-28 |
2024-09-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｇｐｒ１５６変異体及びその使用
|
|
WO2018025089A2
(en)
|
2016-08-05 |
2018-02-08 |
Shin Nippon Biomedical Laboratories, Ltd. |
Pharmaceutical compositions
|
|
US20180064655A1
(en)
|
2016-09-06 |
2018-03-08 |
Steven Sounyoung Yu |
Hydroxynorketamine Transdermal Patch
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US10905897B2
(en)
|
2016-10-20 |
2021-02-02 |
Neuro-Laser Foundation, Inc. |
Synergistic treatment methodologies using light therapy
|
|
US20190240184A1
(en)
|
2016-10-27 |
2019-08-08 |
National University Corporation Chiba University |
Pharmaceutical applications for (s)-norketamine and salts thereof
|
|
US20180177744A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
CN110913844A
(zh)
|
2017-04-20 |
2020-03-24 |
广州大洲生物医药科技有限公司 |
用于氯胺酮的透皮药物递送系统
|
|
CA3105451A1
(en)
|
2017-05-12 |
2018-11-15 |
Indiana University Research And Technology Corporation |
Precision medicine for treating and preventing suicidality
|
|
RU2019143572A
(ru)
|
2017-05-25 |
2021-06-25 |
Глитек Ллс. |
Композиции для лечения посттравматического стрессового расстройства
|
|
DE102017112527B4
(de)
|
2017-06-07 |
2019-01-03 |
Lts Lohmann Therapie-Systeme Ag |
Schnell zerfallende Schaumwafer mit hohem Flächengewicht
|
|
EP3641742B1
(en)
|
2017-06-23 |
2026-03-25 |
Ketabon GmbH |
Hydroxynorketamine for the use in the treatment of depression
|
|
US11331270B2
(en)
|
2017-08-20 |
2022-05-17 |
Nasus Pharma Ltd. |
Dry powder compositions for intranasal delivery
|
|
ES2924188T3
(es)
|
2017-09-25 |
2022-10-05 |
Small Pharma Ltd |
Formas sólidas de dosificación oral de derivados de ketamina
|
|
WO2019065900A1
(ja)
|
2017-09-27 |
2019-04-04 |
国立大学法人千葉大学 |
神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
|
|
EP3698260A4
(en)
|
2017-10-19 |
2021-08-04 |
Eleusis Health Solutions US, Inc. |
METHODS AND SYSTEMS FOR INCREASING THE SAFETY OF AWARENESS-ENHANCING DRUG THERAPIES
|
|
US11491120B2
(en)
|
2017-11-09 |
2022-11-08 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
WO2019099568A1
(en)
|
2017-11-14 |
2019-05-23 |
Bexson Biomedical, Inc. |
Systems, devices, formulations and methods for controlled drug delivery
|
|
DE102017129012A1
(de)
|
2017-12-06 |
2019-06-06 |
Lts Lohmann Therapie-Systeme Ag |
Oraler Dünnfilm mit hoher Wirkstoffbeladung
|
|
MX2020006650A
(es)
|
2017-12-22 |
2020-11-06 |
Janssen Pharmaceuticals Inc |
Esketamina para el tratamiento de la depresión.
|
|
PL3505157T3
(pl)
|
2017-12-29 |
2022-04-11 |
Celon Pharma S.A. |
Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
|
|
IL275968B2
(en)
|
2018-01-10 |
2024-07-01 |
Xwpharma Ltd |
Prodrugs of ketamine, compositions and uses thereof
|
|
AU2019223014B2
(en)
|
2018-02-21 |
2024-10-17 |
Orphai Therapeutics Inc. |
Combination therapy with apilimod and glutamatergic agents
|
|
WO2019178484A1
(en)
|
2018-03-16 |
2019-09-19 |
Intra-Cellular Therapies, Inc. |
Novel methods
|
|
WO2019186357A1
(en)
|
2018-03-26 |
2019-10-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological diseases
|
|
US20230390385A1
(en)
|
2018-04-11 |
2023-12-07 |
Fred M. COWAN |
Compositions and Methods for Prevention and Treatment of Immune Complex Disease
|
|
AU2019262197B2
(en)
|
2018-05-04 |
2024-12-19 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
CN112469396A
(zh)
|
2018-05-31 |
2021-03-09 |
昆士兰大学 |
核壳聚合物纳米颗粒
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
PL3813802T3
(pl)
|
2018-06-27 |
2025-04-22 |
Bioxcel Therapeutics, Inc. |
Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania
|
|
JP2021529732A
(ja)
|
2018-06-27 |
2021-11-04 |
クレキシオ バイオサイエンシーズ エルティーディー． |
大うつ病性障害の処置方法
|
|
US12005142B2
(en)
|
2018-08-02 |
2024-06-11 |
Taiwan Liposome Co., Ltd. |
Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
|
|
US20200038420A1
(en)
|
2018-08-03 |
2020-02-06 |
Enterin, Inc. |
Aminosterol compositions and methods of using the same for treating depression
|
|
US11154537B2
(en)
|
2018-08-10 |
2021-10-26 |
Eleusis Therapeutics Us, Inc. |
Method of treatment for ketamine infusion
|
|
US12090145B2
(en)
|
2018-08-20 |
2024-09-17 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
EP3628313B1
(en)
|
2018-09-28 |
2025-02-12 |
Novohale Therapeutics, LLC |
Ketamine composition for use in a method of treatment of depression by pulmonary administration
|
|
US20210113494A1
(en)
|
2018-10-05 |
2021-04-22 |
Clexio Biosciences Ltd. |
Method Of Treating Post-Traumatic Stress Syndrome
|
|
WO2020086673A1
(en)
|
2018-10-26 |
2020-04-30 |
Guangzhou Dazhou Biomedicine Ltd. |
Ketamine oral transmucosal delivery system
|
|
WO2020089897A1
(en)
|
2018-10-29 |
2020-05-07 |
Hadasit Medical Research Services & Development Limited |
Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
|
|
US11123332B2
(en)
|
2018-11-21 |
2021-09-21 |
Certego Therapeutics Inc. |
Gaboxadol for reducing risk of suicide and rapid relief of depression
|
|
HRP20240255T1
(hr)
|
2019-01-11 |
2024-05-24 |
Alar Pharmaceuticals Inc. |
Ketamin pamoat i njegova uporaba
|
|
CA3127607A1
(en)
|
2019-01-23 |
2020-07-30 |
The Regents Of The University Of Michigan |
Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors
|
|
WO2020168213A1
(en)
|
2019-02-15 |
2020-08-20 |
Massachusetts Institute Of Technology |
Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
|
|
MX2021010683A
(es)
|
2019-03-05 |
2021-12-10 |
Janssen Pharmaceuticals Inc |
Esketamina para el tratamiento de la depresión.
|
|
EP4219498A1
(en)
|
2019-03-07 |
2023-08-02 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
|
|
US12551533B2
(en)
|
2019-03-18 |
2026-02-17 |
New York Medical College |
Intranasal neuropeptides for use in stress-related impairments
|
|
US20220241218A1
(en)
|
2019-04-17 |
2022-08-04 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system
|
|
WO2020223701A1
(en)
|
2019-05-02 |
2020-11-05 |
The Broad Institute, Inc. |
Methods for treating neurodevelopmental disorders
|
|
US12589083B2
(en)
|
2019-05-07 |
2026-03-31 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
WO2020225774A1
(en)
|
2019-05-07 |
2020-11-12 |
Clexio Biosciences Ltd. |
Dosage forms for preventing drug-facilitated assault
|
|
BR112021024138A2
(pt)
|
2019-05-31 |
2022-01-11 |
Celon Pharma Sa |
Sistema para administração supervisionada eletronicamente de uma composição farmacêutica
|
|
CN113905777B
(zh)
|
2019-05-31 |
2025-06-20 |
赛隆制药股份公司 |
用于电子监督胃肠外施用药物组合物的吸入器
|
|
US12502363B2
(en)
|
2019-06-04 |
2025-12-23 |
ADNP Kids Research Foundation |
Ketamine and ketamine/nap for treatment of ADNP syndrome and related neurological conditions
|
|
EP3923920A4
(en)
|
2019-08-05 |
2022-11-23 |
The Ketamine Research Foundation |
KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
|
|
US20220304950A1
(en)
|
2019-08-28 |
2022-09-29 |
Janssen Pharmaceuticals, Inc. |
Esketamine for the treatment of patients with major depressive disorder, including suicidality
|
|
GB201912505D0
(en)
|
2019-08-30 |
2019-10-16 |
Klaria Pharma Holding Ab |
Pharmaceutical formulation
|
|
US20220339123A1
(en)
|
2019-09-13 |
2022-10-27 |
Janssen Pharmaceuticals, Inc. |
Intranasal administration of esketamine
|
|
EP4041226A1
(en)
|
2019-10-02 |
2022-08-17 |
Praxis Precision Medicines, Inc. |
Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists
|
|
CA3156658A1
(en)
|
2019-10-18 |
2021-04-22 |
Institute Of Science And Technology Austria |
NEURONAL PLASTICITY STIMULATION
|
|
WO2021087258A1
(en)
|
2019-10-31 |
2021-05-06 |
The Trustees Of Indiana University |
Compositions and methods for treating alcohol use disorder or a related condition thereof
|
|
WO2021108801A2
(en)
|
2019-11-15 |
2021-06-03 |
Consegna Pharma, Inc. |
Long acting nmda antagonists
|
|
JP2023503271A
(ja)
|
2019-11-18 |
2023-01-27 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
（２ｒ，６ｒ）－ヒドロキシノルケタミンの塩、それらの結晶形、およびその製造方法
|
|
CA3158059A1
(en)
|
2019-11-19 |
2021-05-27 |
Paul Edward Stamets |
Tryptamine compositions for enhancing neurite outgrowth
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
EP4076410B1
(en)
|
2019-12-20 |
2025-09-10 |
Alar Pharmaceuticals Inc. |
Long-acting injectable formulations of ketamine pamoate salts
|
|
WO2021137147A1
(en)
|
2019-12-30 |
2021-07-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
JP2023507926A
(ja)
|
2019-12-30 |
2023-02-28 |
クレキシオ バイオサイエンシーズ エルティーディー． |
神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
|
|
PH12022551856A1
(en)
|
2020-01-22 |
2024-01-03 |
Seelos Therapeutics Inc |
Reducing side effects of nmda antagonists
|
|
DE102020106115A1
(de)
|
2020-03-06 |
2021-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
|
|
WO2021207349A1
(en)
|
2020-04-07 |
2021-10-14 |
Joseph Habboushe |
Prevention and treatment of virial infections
|
|
MX2022014599A
(es)
|
2020-05-20 |
2022-12-16 |
Certego Therapeutics Inc |
Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
|
|
US20230210789A1
(en)
|
2020-06-02 |
2023-07-06 |
Ix Biopharma Limited |
Methods for treating major depressive disorder and treatment-resistant depression
|
|
TW202214218A
(zh)
|
2020-06-19 |
2022-04-16 |
大陸商廣州大洲生物醫藥科技有限公司 |
氯胺酮的透皮給藥系統
|
|
US20210401774A1
(en)
|
2020-06-27 |
2021-12-30 |
Robert Brent Turnipseed |
Ketamine protocols and data evaluation for treatment-resistant depression and trauma
|
|
US20220001014A1
(en)
|
2020-07-01 |
2022-01-06 |
Lida Ghaderi |
Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
|
|
US20220040106A1
(en)
|
2020-08-05 |
2022-02-10 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
EP3949956A1
(en)
|
2020-08-06 |
2022-02-09 |
LTS Lohmann Therapie-Systeme AG |
Esketamine-suspension-tts
|
|
JP7814375B2
(ja)
|
2020-08-18 |
2026-02-16 |
オークウッド ラボラトリーズ，エル．エル．シー． |
ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
|
|
US20230375561A1
(en)
|
2020-09-30 |
2023-11-23 |
Rima F. Kaddurah-Daouk |
Methods for identification, stratification, and treatment of cns diseases
|
|
US20230404914A1
(en)
|
2020-11-09 |
2023-12-21 |
Lts Lohmann Thereapie-Systeme Ag |
Oral thin film
|
|
WO2022109165A1
(en)
|
2020-11-18 |
2022-05-27 |
Indiana University Research And Technology Corporation |
Methods for objective assessment, risk prediction, matching to existing medications and new methods of using drugs, and monitoring responses to treatments for mood disorders
|
|
US11382873B1
(en)
|
2021-01-08 |
2022-07-12 |
Vitalis Analgesics LLC |
Oral administration of ketamine
|
|
IL282188A
(en)
|
2021-04-08 |
2022-11-01 |
Yeda Res & Dev |
Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
|
|
WO2023018966A1
(en)
|
2021-08-13 |
2023-02-16 |
XWPharma Ltd. |
Pharmaceutical compositions and oral dosage forms of ketamine derivatives
|
|
WO2023081109A1
(en)
|
2021-11-05 |
2023-05-11 |
Malcolm Thomas |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
WO2024010935A1
(en)
|
2022-07-07 |
2024-01-11 |
Vitalis Analgesics LLC |
Compositions of aspirin and ketamine
|